[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Joseph C. Wu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100583114","phase-1-a-study-evaluating-the-safety-and-tolerability-of-artesunate-in-patients-with-pulmonary-arterial-hypertension-100583114",false,"NCT06872112","A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","(STOP-PAH)","Inclusion Criteria\n\n* Each participant must meet the following criteria to be enrolled in this study:\n* Adults aged 18 to 75 years.\n* WHO functional class I, II\u002FIII despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.\n\nExclusion Criteria\n\n* Participants who meet any of the following criteria will be excluded from the study.\n* Participants with serious concomitant morbidity per investigator assessment.","ALL","18 Years","60 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.",[28],"Pulmonary Arterial Hypertension (PAH)",[30,31,32],"Pulmonary Arterial Hypertension","Artesunate","PAH","RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-23","ACTUAL",{"date":39,"type":37},"2026-04-01",{"date":41,"type":22},"2029-01-01",{"name":43,"class":44},"Joseph C. Wu","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100515204","phase-1-dose-escalation-study-of-artesunate-patients-with-ipf-100515204","NCT05988463","Dose-Escalation Study of Artesunate Patients With IPF","A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Participants With Idiopathic Pulmonary Fibrosis (SAFE-IPF)","SAFE-IPF","Inclusion Criteria:\n\n1. Participants, aged 40 years or older.\n2. Diagnosis of IPF based upon ATS\u002FERS\u002FJRS\u002FALAT 2018 guidelines (55).\n3. FVC percent of predicted ≥ 40%; historical FVC for entry in the study is permitted if within 3 months of screening.\n4. Diffusing capacity of lung for carbon monoxide (DLco) (hemoglobin-adjusted) ≥ 30%; historical DLco for entry in the study is permitted if within 3 months of screening.\n5. Participants currently receiving treatment for IPF with nintedanib or pirfenidone are allowed, provided these drugs have been given at a stable dose for at least 6 weeks before the Screening visit (stable dose is defined as the highest dose tolerated by the participant during ≥ 6 weeks).\n6. Female participants of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male participants with sexual partners of childbearing potential must use highly effective methods of birth control during their participation in the study and for 60 days after the last administration of study drug. Highly effective methods of birth control are defined as those with 99% or greater efficacy.\n7. Participants must agree to abstain from egg or sperm donation through 60 days, after administration of the last dose of study drug.\n8. Able to read and sign a written informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Receiving any nonapproved agent intended for treatment of fibrosis in IPF or Participation in other clinical trials.\n2. Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, or sinusitis that can affect FVC measurement during screening.\n3. Known acute IPF exacerbation or suspicion by the Investigator of such, within 3 months of screening.\n4. The extent of emphysema is greater than the fibrotic changes on the most recent HRCT scan as determined by PI.\n5. Any medical condition, not limited to cardiac, hepatic, renal disease or malignancy in recent months that will make the patients ineligible for the study, as deemed significant by PI.\n6. Any of the following liver function test criteria above specified limits: total bilirubin \\>2× the upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3× ULN; alkaline phosphatase \\> 2.5× ULN, pending PI's discretion.\n7. Hemoglobin levels \\\u003C 10.0 g\u002FdL.\n8. Pregnant or lactating females.\n9. Likely to have lung transplantation during the study (being on transplantation list is acceptable).\n10. Currently receiving and expected to remain on treatment during the study with: amodiaquine, and efavirenz, nevirapine and ritonavir.","40 Years",{"count":21,"type":22},[25],"Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by 12 weeks of oral artesunate treatment across 3 dose levels (dose escalation every 4 weeks), and 4 weeks of a washout (follow-up) period in participants with Idiopathic Pulmonary Fibrosis (IPF). The primary objective of the study is to evaluate the safety and tolerability of artesunate at 3 dose levels, and to select the dose(s) to carry forward into additional clinical testing. The secondary objective includes exploring the blood biomarkers present in participants with IPF at baseline and to investigate how those biomarkers change following artesunate treatment. The exploratory objectives include assessing the changes in the K-BILD and Leicester cough questionnaire scores and change in pulmonary function after artesunate administration.",[59],"Idiopathic Pulmonary Fibrosis",[61],"shortness of breath, fibrosis, cough, hypoxemia","2026-01-07",{"date":64,"type":37},"2026-01-09",{"date":66,"type":22},"2027-01-01",{"date":68,"type":22},"2028-11-01",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100444533","phase-1-human-embryonic-stem-cell-derived-cardiomyocyte-therapy-for-chronic-ischemic-left-ventricular-dysfunction-100444533","NCT05068674","Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction","A Phase I, Randomized Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes (hESC-CMs) in PaTients With ChrOnic Ischemic Left VentRicular Dysfunction Secondary to Myocardial Infarction (HECTOR)","HECTOR","Inclusion Criteria:\n\n* Be ≥ 21 and \\\u003C 80 years of age.\n* Provide written informed consent.\n* Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.\n* Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.\n* Have been treated with appropriate maximal medical therapy for heart failure or postinfarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs) or have appropriate medical indication precluding use of one or both of these agents, the patient must have been on a stable dose of a clinically appropriate agent for 1 month or within no more than doubling the dose of any of ARB, ACE inhibitors, and ARNIs over the last 3 months.\n* Left ventricular ejection fraction below 40%.\n* Class II\u002FIII NYHA symptoms of heart failure within the 6 months prior to baseline testing.\n* Hospitalization in the past 6 months or NT pro-BNP \\> 1200 pg\u002FmL, or \\>1600 pg\u002FmL if atrial fibrillation was present.\n* Automated implantable cardioverter-defibrillator (AICD) in place.\n\nExclusion Criteria:\n\n* Have a baseline glomerular filtration rate \\\u003C 35 ml\u002Fmin\u002F1.73 m2\n* Have a known, serious radiographic contrast allergy.\n* Have a prosthetic aortic valve or heart constrictive device.\n* Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5 cm2 or less).\n* Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).\n* Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second- or third-degree heart block in the absence of a functioning pacemaker) or QTc interval \\> 550 ms on screening ECG.\n* AICD firing in the past 60 days prior to enrollment.\n* Be eligible for or require coronary artery revascularization.\n* Have a hematologic abnormality as evidenced by hematocrit \\\u003C 25%, white blood cell \\\u003C 2,500\u002Fµl, or platelet values \\\u003C 100,000\u002Fµl without another explanation.\n* Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.\n* Have a coagulopathy (INR \\> 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \\\u003C 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment.\n* Have known allergies to penicillin or streptomycin.\n* Be an organ transplant recipient.\n* Have a history of organ or cell transplant rejection.\n* Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.\n* Have a non-cardiac condition that limits lifespan to \\\u003C 1 year.\n* Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.\n* Be serum-positive for HIV, hepatitis BsAg, or viremic hepatitis C.\n* Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\n* Be a female patient who is pregnant, nursing, or have child-bearing potential but is not using effective birth control.\n* Tested positive for SARS-CoV-2 within the last 30 days","21 Years","80 Years",{"count":81,"type":22},18,[25],"This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).",[85],"Chronic Ischemic Left Ventricular Dysfunction","2025-09-25",{"date":88,"type":37},"2025-09-29",{"date":90,"type":37},"2022-03-22",{"date":92,"type":22},"2028-10",{"name":43,"class":44},""]